For practically a decade, Flagship poured record-setting ranges of money into Moderna, whilst they confronted setbacks on early applications and skeptics questioned whether or not the corporate’s science may ever match its hype.
Now that the science has delivered, Flagship is cashing in.
Over the past 13 months, because the World Well being Group declared a pandemic, Flagship has bought off Moderna shares value $1.4 billion. The gross sales, first reported by Forbes, got here because the Cambridge biotech’s shares soared from slightly below $20 per share on Jan. 3, 2020, to $169.50 when markets opened Thursday.
Preserve studying Endpoints with a free subscription
Unlock this story immediately and be a part of 103,900+ biopharma execs studying Endpoints every day — and it is free.